Group items tagged

The Pharmacists' Defence Association (PDA) is playing a vital role in helping pharmacists who are dealing with stress at the workplace. It launched its new awareness factsheet 'It's Time to Address Stress' last week. The factsheet looks at the causes and symptoms of stress in the workplace and provides advice on ways pharmacists can access support and improve working conditions. The association said that it recognises the well-being services offered by employers and specialist charities such as the PDA's charity partner Pharmacist Support play an important part in helping pharmacists who may be experiencing stress. However, the PDA is also committed to working with members to challenge employers to provide well workplaces and to help them to make real impact changes. This can be done by addressing the causes of stress and fulfilling their responsibilities to their employees. It added: "Under the management of Health and Safety at Work Regulations 1999, employers are required by law to protect employees from harm. Their legal obligations include identifying hazards and risks and implementing ways to reduce or eliminate them. The PDA's new factsheet highlights the importance of employers recognising the hazards causing stress as the health and safety issues they are."

The latest inspection report of the General Pharmaceutical Council (GPhC) revealed that nine pharmacies did not meet their standards out of 52 pharmacies that were inspected between January 2023 and May 2023. Pharmacies are inspected on five principles - Governance, Staff, Premises, Services including medicines management and Equipment and facilities. Out of nine, eight pharmacies did not meet GPhC standard of governance which is defined to safeguard the health, safety and wellbeing of patients and the public. Six pharmacies did not meet the GPhC standard of principle four which defines the way in which pharmacy services, including the management of medicines and medical devices, are delivered safeguards the health, safety and wellbeing of patients and the public. The purpose of these standards is to create and maintain the right environment, both organisational and physical, for the safe and effective practice of pharmacy. The standards apply to all pharmacies registered with GPhC.

The Medicines and Healthcare products Regulatory Agency (MHRA) has launched new guidance to highlight the latest safety advice on the steps to take during anaphylaxis. On the start of World Allergy Week (19 June), an annual initiative led by the World Allergy Organization, aiming to raise awareness of allergies, their management and prevention, the MHRA has collaborated with allergy awareness advocates to share an easy step-by-step infographic guide and video outlining the latest advice from the CHM's working group on the safe and effective use of AAIs. Steve Barclay, Secretary of State for Health and Social Care said: "A severe allergic reaction can be life-threatening. One in five people in the UK suffer with at least one allergy, so it's vital people are equipped with the knowledge to keep themselves safe. Adrenaline auto-injectors - also known as AAIs or by their brand names such as EpiPen - are highly effective and convenient for the immediate treatment of anaphylaxis. If you have been prescribed one, please carry it with you at all times and make sure you are up to date on the latest safety guidance - it could save your life."

Royal Pharmaceutical Society (RPS) and the Royal College of General Practitioners in Scotland hosted an event celebrating the collaborative work of the health professions and policy makers in Scotland on reducing the environmental harm from prescribing and medicines use. To share priorities for the Scottish Government, Alpana Mair, Head of Effective Therapeutics and Prescribing spoke and National Clinical Director Jason Leitch appeared virtually. Gillian MacKay MSP, Scottish Greens spokesperson for Health and Social Care also joined in-person. Medicines account for around 25% of the NHS's carbon emissions and have an ecological impact when they enter our wastewater system or our rivers and oceans. Tackling the impact of prescribing will be a key part of meeting the ambition of a net zero NHS Scotland by 2040 at the latest. Together, RCGP Scotland and RPS have held two roundtable events on sustainable prescribing, and in June 2022, released a joint statement calling for a wide range of actions, which was signed by the Academy of Medical Royal Colleges and Faculties in Scotland, the Royal College of Physicians of Edinburgh, the Royal College of Anaesthetists, the College of Radiographers, Royal College of Nursing, Queen's Nursing Institute Scotland and Chartered Society of Physiotherapy. Continuing the work of RPS at the International Forum on Quality and Safety in Healthcare, the event aims to mark an opportunity for health professionals and decision makers alike to join a global movement of sustainability in healthcare, and pledge to continue the important work of cutting the climate impact of medicine use while maintaining the highest level of patient care and safety.

Britain has approved Novavax's Covid-19 vaccine for use in those 18 years of age and older, the country's medicines regulator said on Thursday (February 3), bringing a fifth coronavirus shot to its roster amidst the rapid spread of the Omicron variant. The vaccine, Nuvaxovid, was approved as a first and second dose as it met the required safety, quality and effectiveness standards, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) said in a statement. The British approval for Nuvaxovid comes days after the drugmaker filed for US authorisation of the vaccine following months of struggles with development and manufacturing problems, and follows a German backing earlier in the day. "We are continuing our vital safety work in monitoring the use of all Covid-19 vaccines, to ensure that their benefits in protecting people against Covid-19 disease continue to outweigh any risks," MHRA chief executive June Raine said.

Following concerns raised about cracked cartridges and insulin leaks, the Medicines and Healthcare products Regulatory Agency (MHRA) has issued a national patient safety alert for the NovoRapid PumpCart prefilled insulin cartridge and the Roche Accu-Chek Insight Insulin pump system. The regulator have asked patients to check the pre-filled glass insulin cartridge for cracks before use. It advised against using the cartridge if it has been dropped even if no cracks are visible and urged to closely follow the updated handling instructions in the pump user manual when changing pre-filled glass insulin cartridges. In some of the reported leakage incidents, the cartridges were found to be cracked and provided an inadequate supply of insulin to patients. Leakages also occurred in cases where no cracks in the cartridge were visible, the regulator said. In some patients there were consequences of not receiving enough insulin from their pump system, including reports of severely high blood sugar and diabetic ketoacidosis, a serious complication of diabetes when the body produces high levels of blood acids called ketones. Healthcare professionals are being advised to contact patients over the next six months using said device to discuss their individual needs and source an alternative pump where appropriate. "Because of the rare risk of insulin leakage from the Roche Accu-Chek Insight Insulin Pump, patients should check the pre-filled glass insulin cartridge for any cracks prior to usage," Dr June Raine, MHRA chief executive, said.

Violent and abusive behaviour against pharmacists is impacting on recruitment and retention of staff in the sector, according to the Pharmacists' Defence Association (PDA). The trade union for pharmacists told BBC Breakfast TV on Wednesday (May 8) that its members have continuously raised workplace safety concerns due to an alarming rise in the incidents of abuse and violence against pharmacy staff. The PDA union has been calling for adequate risk assessments and preventative safety measures to be put in place in pharmacies whist adopting a zero-tolerance approach to violence and abuse. With several significant and worrying incidents involving PDA members, including a pharmacist being threatened with a knife recently, further research was conducted in April 2022 to establish the extent and impact of such behaviour on pharmacists. Forty-four per cent of the respondents in the survey reported that they or someone that they worked with had experienced physical or violent abuse in the last month.

Working conditions in pharmacies have worsened in 2021, the annual Safer Pharmacies Survey conducted by the Pharmacists' Defence Association (PDA) revealed, highlighting the challenging and unsafe environments that some pharmacists are working in. The survey asks pharmacists across all areas of practice about their experiences of key safety measures in the workplace. Since the launch of the Safer Pharmacies Charter in 2017, PDA's annual surveys have monitored their feedback against the Charter's commitments, which covers seven basic areas as standard practice for pharmacy work. The commitments are No Self-Checking, Safe Staffing, Access to a Pharmacist, Adequate Rest, Respect for Professional Judgment, Raising Concerns and Physical Safety. The survey revealed that eight out of 10 feel unsafe at work as violence and abuse still remain areas of concerns in pharmacy.

Pharmaceutical recalls are complicated and expensive, just like in any other business. Pharmaceutical recalls, however, pose a further risk because they might change both short- and long-term health effects. To ensure smooth recalls with few negative effects on public health, it is crucial to understand the pharmaceutical product recall procedure and the roles of each key player. Throughout the recall procedure, patient safety is crucially ensured by the FDA, pharmaceutical companies, pharmacy technicians, and other healthcare professionals. Learning about pharma recalls, procedures, and responsibilities is essential for guaranteeing patient safety for key actors like the Food and Drug Administration (FDA), manufacturers, and other medical specialists. RECALL CLASSIFICATIONS Recalls can fall into one of three categories-class I, II, or III-with class I being the most serious and lethal. Products that have the potential to result in serious, permanent complications or death are subject to Class I recalls. Class II recalls are recommended for product flaws that have a low likelihood of harmful events or that can result in reversible side effects. Last but not least, class III recalls typically arise from problems with packaging that do not pose a risk. Since they are frequently issued out of an abundance of prudence rather than due to any negative impacts, many people may even describe this kind of recall as benign.

In a recent announcement the Medicines and Healthcare products Regulatory Agency (MHRA) unveiled its strategic approach to artificial intelligence (AI), as it sets out to embrace the transformative potential of AI in healthcare regulation. Building upon the Government's white paper 'A pro-innovation approach to AI regulation', released in 2023, the MHRA outlined five key strategic principles guiding its adoption of AI. These principles encompass safety, security, and robustness; appropriate transparency and explainability; fairness, accountability, and governance; and contestability and redress. A science-led organization, the MHRA was tasked with providing an independent view of its approach to AI in medicine and science, aligning with a government white paper. Recognising its role in UK's goal to be a science and tech leader by 2030, MHRA is tasked to evaluate AI's opportunities and risks across regulatory, public service, and evidence-based decision-making area.

The Medicines and Healthcare products Regulatory Agency (MHRA) has advised the public to exercise caution when buying anti-choking devices online, ensuring these products are purchased from reputable sellers. As estimated by the regulator, more than 10,000 counterfeit or unbranded anti-choking devices have been purchased by the public within the last two years through listings on online marketplaces such as Amazon and eBay, as well as drop-shipping websites. People are cautioned that the use of such products poses a substantial risk of failure in clearing blockages and could exacerbate the situation by pushing obstructions further down into the airway passage. Dr Alison Cave, MHRA Chief Safety Officer, said: "Buying anti-choking devices that do not have a valid UKCA or CE mark increases the risk of receiving a product which does not include appropriate instructions and is either fake or does not meet the UK's regulatory requirements. "These products do not meet our strict quality standards and may put your health and safety at significant risk by failing to resolve or even worsening choking incidents."

In a bid to bolster professional leadership within the pharmacy sector, the four government Chief Pharmaceutical Officers (CPhOs) have embarked on a significant initiative, forming the UK Pharmacy Professional Leadership Advisory Board (UKPPLAB). In a recent communication, all pharmacists and pharmacy technicians received confirmation of the board members selected by the CPhOs, alongside a note from the board's appointed chair, who was chosen collectively by the four CPhOs and reports directly to the CPhO for England. Over three years, the 21-member Board will implement recommendations from the UK Commission on Pharmacy Professional Leadership's report aimed to enhance professional fulfillment among pharmacists while simultaneously augmenting patient safety standards. This announcement also follows with the appointment of Sir Hugh Taylor as its Independent Chair and the appointment of Independent Expert Members who expressed his delight over the role's "potential to lead and support collaboration across the professions in the UK". However, the move has been met with cautious optimism from the Pharmacists' Defence Association (PDA), urging the new board to uphold transparency and openness to garner trust among pharmacists.

The Food Standards Agency (FSA) has launched a campaign to caution people with food allergies about the risk of products labelled as 'vegan'. People who have an allergy to milk, eggs, fish and crustaceans or molluscs are encouraged to always check for a precautionary allergen statement such as 'may contain' on products labelled 'vegan' before consuming the food. The launch of the campaign comes in the wake of recent research findings by the FSA that 62 per cent of individuals with reactions to animal-based products or who buy for someone with allergies were confident that products labelled 'vegan' are safe to eat. This is "incorrect" and may put them at risk, the agency said. The FSA study found that 54 per cent of people who experience reactions to animal-based products and 53 per cent of those purchasing for someone with a food hypersensitivity to animal-origin products have used vegan labelling to determine the safety of packaged food on at least some occasions.

The Pharmacists' Defence Association (PDA) has written to the National Pharmacy Association (NPA) to highlight several important points regarding their proposed "day of action" on 20 June 2024. The NPA describes this initiative as a response to the "emergency across the community pharmacy sector." In a letter addressed to NPA Chair Nick Kaye and Chief Executive Paul Rees, the PDA's director of pharmacy, Jay Badenhorst stressed the need for NPA members to consider their obligations to staff and patients before participating in the planned actions. He stated, "We are supportive of a new contractual framework for the community pharmacy sector." "However, any actions taken must ensure the safety of patients and the operational integrity of pharmacies." The PDA's letter also expressed concerns over the safety and operational impact of the proposed symbolic gestures, including turning off lights and blacking out windows.

The International Pharmaceutical Federation (FIP) has announced its support for the Pharmacists' Defence Association (PDA)'s Safer Pharmacies Charter, which aims to improve safety and care for patients, through better working conditions in UK pharmacy practice. The Charter establishes basic standards to ensure safe practices across all pharmacy settings. It outlines seven commitments that, according to the PDA, "must be standard practice whenever and wherever pharmacy work is carried out." Dr Catherine Duggan, FIP CEO, said: "We are pleased to support the PDA's Safer Pharmacies Charter which defines basic standards to ensure safe practice wherever pharmacists work. "The overall objectives of the Charter align with FIP's development goals and overall mission." FIP, the global body representing pharmacy and pharmaceutical sciences, plans to distribute the Charter among its members and share it with its Community Pharmacy Section for information purposes.

A judicial review claim launched by the British Medical Association (BMA) against the General Medical Council (GMC) has parallelly intensified Pharmacists' Defence Association's (PDA) scrutiny over the use of the term 'pharmacy professionals'. PDA has criticised the evolving definition of 'pharmacy professionals,' and the potential risks to patient safety amidst regulatory ambiguity as part of "a far wider agenda." Concerns stem from what the PDA perceives as a blurring of distinctions between pharmacists and pharmacy technicians as "attempted homogenisation" by bodies like the General Pharmaceutical Council (GPhC), NHS, and Royal Pharmaceutical Society (RPS). Raising similar issue as the BMA against the GMC over its use of 'medical professionals for doctors and Medical Associate Professions (MAPs), Mark Koizol, Chairman of the PDA has said:

As America reopens and adjusts to the new normal, medical practices have a responsibility to fulfill. They have to implement the safety protocols within their clinics and continue to save lives. We have brought forward five tips to align your practice with the social distancing protocols; to keep it as a place where people heal rather than the opposite.

A new Information Standard has been published to support improved medication and sharing of allergy information across healthcare services in England. The move will standardise medication message content and help reduce medicines related errors and improve patient safety. It will also allow efficient sharing of medicine information between NHS and social care organisations, including hospitals, GP practices, residential care homes, mental health trusts, and community pharmacies. The Standard that came into effect in October "will save healthcare professionals valuable time accessing key medicines information, provide clinicians with access to a richer source of information, consistent across all care settings", said Shahzad Ali, NHS Digital clinical lead for the Interoperable Medicines Programme.

Storing your medication properly is important. Only if they have their place in the house will you and your family members always know where to find their supplements, pain relief medications, and others. In this article, we'll try to give you some guidelines on how to manage your medication and develop a system that will work well for you and your family. Also, since medicine safety is so important, we'll share some simple tips on making sure all medications are good and when is the right time to toss them. 1. USE A BOX 2. KEEP YOUR MEDICATION IN A COLD AND DRY PLACE 3. COLOR CODE YOUR MEDICATION 4. DISPOSE OF MEDICINE 5. ORGANIZE YOUR MEDICINE ON THE GO 6. KEEP IT NEAT Once you find a place where medicine won't experience extreme temperatures, humidity, and strong sunlight, get a nice set of boxes and take one afternoon to make it neat and organized. Even if you're taking specific medication, ask your pharmacist what's the best place to store them. Sometimes, it might turn out that it's your fridge, but a kitchen might also be a good place to start thinking about.

The Medicines & Healthcare products Regulatory Agency has initiated a recall of three batches of Quantum Pharmaceutical's Diltiazem HCl 2% Cream, which is an unlicensed medicine. MHRA issued a precautionary recall of the cream due to a change in the product's appearance that affected its thickness. Pharmacists are instructed to halt supply, quarantine remaining stock, and contact Quantum Pharmaceutical to return affected batches M1402497, M1402574, and M1402680. Patients using this product may encounter application issues with the cream due to its consistency. However, MHRA said that this has not impacted the product's effectiveness or posed any risk to patient safety. The MHRA also reported that medac GmbH (t/a medac Pharma LLP) is conducting a recall of two batches of Sodiofolin 50 mg/ml solution for injection/infusion (400mg/8ml vial) with batch numbers G220393B and G220393C. This class 2 medicines recall is a result of particles detected during long-term stability tests.